

**EDRN Planning and Steering Committee Meeting  
October 19-21, 2016  
DoubleTree by Hilton Bethesda  
Bethesda, Maryland**

**Lung and Aerodigestive Cancers Collaborative Group Meeting**

**Thursday, October 20, 2016  
8:50 a.m. – 12:00 p.m.**

**Team Building Session:  
1:00 p.m. – 3:00 p.m.**

**Insight Room**

**Moderator:**

Harvey Pass, M.D., New York University School of Medicine

**NCI Program Directors:**

Lynn Sorbara, Ph.D. and Karl Krueger, Ph.D., National Cancer Institute

**Agenda**

**8:50 a.m. – 9:00 a.m.**

**Welcome**

Lynn Sorbara, Ph.D., National Cancer Institute

**9:00 a.m. – 12:00 p.m.**

**Morning Session: Short Presentations by PIs**

*9:00 a.m. – 9:20 a.m.*

Ultrasensitive Detection of Tumor Specific DNA Methylation Changes for the Early Detection of Lung Cancer

James Herman, M.D., University of Pittsburgh Cancer Institute

*9:20 a.m. – 9:40 a.m.*

Moffitt Imaging Biomarker Validation Center

Jae K. Lee, Ph.D., H. Lee Moffitt Cancer Center and Research Institute

*9:40 a.m. – 10:00 a.m.*

Validation of Biomarkers of Risk for the Early Detection of Lung Cancer

Pierre P. Massion, M.D., Vanderbilt-Ingram Cancer Center

*10:00 a.m. – 10:20 a.m.*

The EDRN Mesothelioma Biomarker Discovery Laboratory

Harvey Pass, M.D., New York University School of Medicine

**10:20 a.m. – 10:30 a.m.**

**Break**

**EDRN Planning and Steering Committee Meeting**  
**October 19-21, 2016**  
**DoubleTree by Hilton Bethesda**  
**Bethesda, Maryland**

**Lung and Aerodigestive Cancers Collaborative Group Meeting**  
**(Continued)**

**Short Presentations by PIs (Continued)**

- |                                |  |
|--------------------------------|--|
| <i>10:30 a.m. – 10:50 a.m.</i> | <u>Integration of Biomarker Signatures from Peripheral Blood for Diagnosis, Prognosis, Remission and Recurrence of Lung Cancer</u><br>Louise Showe, Ph.D., The Wistar Institute  |
| <i>10:50 a.m. – 11:10 a.m.</i> | <u>The Boston University-UCLA Lung Cancer Biomarker Development Laboratory</u><br>Avrum Spira, M.D., Boston University   |
| <i>11:10 a.m. – 11:30 a.m.</i> | <u>University of Maryland, Baltimore Biomarker Reference Laboratory</u><br>Sanford Stass, M.D., University of Maryland   |
| <i>11:30 a.m. – 11:50 a.m.</i> | <u>DNA Repair Enzyme Risk Biomarkers for Lung Cancer</u><br>Zvi Livneh, Ph.D., Weizmann Institute of Science   |
| <b>11:50 a.m. – 12:00 p.m.</b> | <b>Final Discussions/Questions</b>   |
| <b>12:00 p.m. – 1:00 p.m.</b>  | <b>Lunch (On Your Own)</b>   |
| <b>1:00 p.m. – 3:00 p.m.</b>   | <b>Afternoon Session: Team Building</b>  |
| <i>1:00 p.m. – 1:50 p.m.</i>   | Discussions: Projects Supported by Set-Aside Funds<br>Development and verification of standard resources (including biospecimens) and methodologies (cross-organ site and platform studies)  |
| <i>1:50 p.m. – 2:40 p.m.</i>   | Discussions: Projects Supported by Core Funds <ul style="list-style-type: none"><li>○ Multi-site validation trials</li><li>○ Patient accrual and biospecimen collections using SOPs and CDEs</li><li>○ Validation of multiple markers/panels using the same biospecimens</li></ul> |
| <i>2:40 p.m. – 3:00 p.m.</i>   | Wrap up: Results of discussion will be presented to the entire EDRN from 3-4 p.m.  |